IBI321 / Innovent Biologics, Eli Lilly - LARVOL DELTA

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Feb 2023

Metastases • Trial completion • Trial completion date • Oncology • Solid Tumor

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1a/1b | N=16 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting ➔ Completed | N=116 ➔ 16 | Trial completion date: Jul 2024 ➔ Feb 2023

Enrollment change • Metastases • Trial completion • Trial completion date • Oncology • Solid Tumor

A Dose Escalation Study of IBI321 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1a/1b | N=116 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=110; Not yet recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Clinical • Combination therapy • Monotherapy • New P1 trial • Oncology • Solid Tumor

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1a/1b; N=116; Recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors (PRNewswire) - "Innovent Biologics...announced that the first patient has been dosed in a Phase 1 study of IBI321, an anti-PD-1/TIGIT bispecific antibody. The objective of this open-label, multi-center Phase 1a dose escalation and expansion study is to evaluate the safety, tolerability, potential optimal dosage and preliminary efficacy of IBI321 in patients with advanced malignant tumors whose cancer progressed on standard-of-care treatment. The trial is being conducted in China."

Trial status • Oncology • Solid Tumor

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor

A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1a/1b; N=116; Not yet recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor

Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress (PRNewswire) - “The Company plans to enter phase III or pivotal clinical trial this year for 1L MDS for IBI-188…The Company plans to obtain proof-of-concept (PoC) data for IBI-322 in 2021…The Company has completed phase 1b enrollment for IBI-110 and will obtain PoC data in 2021. The potential first-in-class PD- L1/LAG-3 bispecific antibody has also received IND approval recently, and the Company will start Phase 1 study in 2021…In TIGIT area: the TIGIT monoclonal antibody IBI-939 has entered Phase 1b study, with plan to obtain PoC data in 2021. The Company also submitted the IND application for its PD-1/TIGIT bispecific antibody IBI-321 recently, and plans to start clinical study in 2021.”

New P1 trial • New P3 trial • P1 data • Myelodysplastic Syndrome • Oncology • Solid Tumor